Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation - Top-Institutions - MDSpire

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

  • By

  • Caroline Foxton

  • Bradley Waldron

  • Alexander Wurzer

  • Calogero D’Alessandria

  • Alfred Morgenstern

  • Frank Bruchertseifer

  • Tea Kirkegaard Nielsen

  • Rikke Veggerby Grønlund

  • Mathias Wikke Hallund

  • Daniel J. Stevens

  • July 16, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    University Hospital Essen
    University Hospital Essen

    Essen, NRW

    Key Differentiators

    • Nuclear Medicine
    • Oncology

  • #3

    University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
    University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center

    Los Angeles, CA

    Key Differentiators

    • Oncology

Original Source(s)

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

  • by Caroline Foxton, Bradley Waldron, Alexander Wurzer, Calogero D’Alessandria, Alfred Morgenstern, Frank Bruchertseifer, Tea Kirkegaard Nielsen, Rikke Veggerby Grønlund, Mathias Wikke Hallund, Daniel J. Stevens

  • July 16, 2026

Related Content

Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis

Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges

Ten reasons why acute respiratory failure is different in the immunocompromised host